Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 13/20 | 0.70 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8224560 | 0.85 | CACNA1H (0.88) | CACNA1HS1PR2 | |
| SCHEMBL13595937 | 0.84 | CACNA1H (0.67) | CACNA1HS1PR2 | |
| SCHEMBL8218790 | 0.83 | CACNA1H (0.73) | CACNA1HS1PR2 | |
| SCHEMBL13595944 | 0.82 | CACNA1H (1.00) | CACNA1HS1PR2KMT2AALDH1A1CYP2D6 | |
| SCHEMBL8218859 | 0.80 | CACNA1H (1.00) | CACNA1HS1PR2ALDH1A1CYP2D6 | |
| SCHEMBL4302495 | 0.75 | LMNA (0.53) | CACNA1HKMT2AALDH1A1 | |
| SCHEMBL8225771 | 0.75 | CACNA1H (0.83) | CACNA1HS1PR2ALDH1A1CYP2D6 | |
| SCHEMBL8218935 | 0.74 | CACNA1H (0.89) | CACNA1HS1PR2ALDH1A1CYP2D6 | |
| SCHEMBL13595943 | 0.74 | CACNA1H (1.00) | CACNA1HS1PR2 | |
| SCHEMBL8227789 | 0.73 | CACNA1H (0.34) | CACNA1HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638526-B2 | Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638526-B2 | Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
| WO-2008033456-A1 | SPIRO-CONDENSED AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABILISM | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | GPR119, PNLIP, CYP46A1 | CACNA1H 1192/4885S1PR2 745/4885KMT2A 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.